CIK细胞治疗转移性肾细胞癌21例临床疗效观察  

The clinical efficacy of cytokine induced killer cells in 21 patients with metastatic renal cell carcinoma

作　　者：李威[1] 赵玲娣[1] 王黎[1] 张勇[1] 张小杰[1] 杨勇豪[1] 高全立[1] 买玲[2] 

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院),450003 [2]河南省肿瘤医院肿瘤研究院,郑州450003

出　　处：《国际免疫学杂志》2013年第2期154-157,共4页International Journal of Immunology

摘　　要：目的评价细胞因子诱导的杀伤细胞（CIK）细胞治疗转移性肾癌（MRCC）的临床疗效。方法2010年5月至2011年11月入住河南省肿瘤医院（郑州大学附属肿瘤医院）生物治疗科经病理确诊的21例MRCC患者，所有患者均接受至少4周期CIK细胞治疗。治疗后定期复查，评价疗效。主要观察指标为疾病控制率（DCR）和至疾病进展时间（TTP），次要观察指标为不良反应发生率和影响患者TTP的因素，主要观察指标TTP采用Kaplan—Meier方法分析，影响1rrP的因素采用Log—Rank方法分析。结果21例患者中部分缓解（PR）1例，疾病稳定（SD）16例，疾病进展（PD）4例，疾病控制率（DCR）为80．95％（17／21），中位TTP为11．68个月；所有患者主要不良反应是发热，发生率为19．05％（4／21）；亚组分析表明发生肺转移的、CIK细胞治疗周期多的患者具有更长的TTP，差异具有统计学意义P〈0．05。结论CIK细胞是转移性肾癌患者安全、有效的治疗方法，疗效和靶向治疗的疗效相当。但患者不良反应小，耐受性良好．肺转移患者及CIK细胞治疗周期多的患者TTP更长。Objective To investigate the clinical efficacy of cytokine induced killer cells（CIK） for the treatment of metastatic renal cell carcinoma （MRCC）. Methods We analyzed 21 cases of MRCC, who received more than 4 cycles CIK cells therapies. All the patients were from the department of biotherapy of He Nan cancer hospital. Our primary endpoints were disease control rate （DCR） and time to progression （TYP）, secondary endpoints were incidence of adverse reactions and the influencing factors for TFP, all data were through statistical analysis. Results Of the 21 patients, 1 had partial remission（ PR）, 16 had stable disease （SD） , 4 had with progressed disease （PD） , DCR（ PR ＋ SD） accounted for 80.95% （ 17/21 ）. The overall median TTP was 11.68 months. Patients with lung metastasis or/and more than 6 might have longer TTP than other patients（ P 〈 0.05 ）. Conclusion CIK cells therapy is safe and efficacy for MRCC, which have the equal efficacy of targeted therapy. However, adverse events are lower than targeted therapy and patients are well tolerated, patients with lung metastasis or increasing the cycles of CIK cell therapy may prolong TFP of patients with MRCC.

关 键 词：转移性肾细胞癌 细胞因子诱导的杀伤细胞 临床疗效 

分 类 号：R737[医药卫生—肿瘤]